Cytokinetics
CYTK
277 hedge funds and large institutions have $4.88B invested in Cytokinetics in 2022 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 109 increasing their positions, 83 reducing their positions, and 36 closing their positions.
356% more call options, than puts
Call options by funds: $48.3M | Put options by funds: $10.6M
31% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 83
1.22% more ownership
Funds ownership: 111.13% → 112.35% (+1.2%)
6% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 36
0% more funds holding
Funds holding: 277 → 277 (0)
1% less capital invested
Capital invested by funds: $4.95B → $4.88B (-$70.7M)
9% less funds holding in top 10
Funds holding in top 10: 11 → 10 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$73.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$34M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
+$30.9M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$25.7M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$23.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$53.4M |
| 2 |
CC
Commodore Capital
New York
|
-$43.3M |
| 3 |
DM
Deerfield Management
New York
|
-$39.4M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$35.9M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$22.1M |
CYTK Hedge Fund Activity: Q4 2022 in Review
277 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2022, worth a combined $4.88B — down 1.4% from $4.95B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new CYTK positions and 36 closed out — a net gain of 2 holders — while 109 added to existing stakes and 83 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $73.4M. The largest seller was Driehaus Capital Management, cutting an estimated $53.4M.
- 277 institutional investors held Cytokinetics (CYTK) as of Q4 2022, unchanged from Q3 2022.
- Funds reported $4.88B of Cytokinetics stock for Q4 2022, down 1.4% quarter-over-quarter.
- 38 funds opened new Cytokinetics positions in Q4 2022 and 36 closed out, a net change of +2 holders.
- The largest Cytokinetics buyer in Q4 2022 was Wellington Management Group, an estimated $73.4M added.
- The largest Cytokinetics seller in Q4 2022 was Driehaus Capital Management, an estimated $53.4M sold.
Based on aggregated 13F filings for Q4 2022.